Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin

被引：11

作者：

Zeremski, Marija ^{[1
]}

Dimova, Rositsa B. ^{[2
,3
]}

Benjamin, Samantha ^{[1
]}

Penney, Marina S. ^{[4
]}

Botfield, Martyn C. ^{[4
]}

Talal, Andrew H. ^{[1
,2
]}

机构：

[1] Weill Cornell Med Coll, Div Gastroenterol & Hepatol, New York, NY 10065 USA

[2] SUNY Buffalo, Dept Med, Div Gastroenterol Hepatol & Nutr, Buffalo, NY 14260 USA

[3] SUNY Buffalo, Dept Biostat, Buffalo, NY 14260 USA

[4] Vertex Pharmaceut, Boston, MA USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2015年 / 211卷 / 11期

关键词：

HCV; CXCL10; chemokines; liver inflammation; CHEMOKINES; THERAPY; LIVER; HEPATOCYTES; ACTIVATION; PROTEIN-10; INDUCTION; CORRELATE; FIBROSIS; KINETICS;

D O I：

10.1093/infdis/jiu807

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We assessed peripheral and liver CXCL10 levels in 15 patients treated with telaprevir/pegylated interferon/ribavirin. Induction of peripheral CXCL10 messenger RNA (mRNA) peaked (mean fold-induction [+/- SD], 3.1 +/- 1.9) between treatment hour 6 and day 2, while induction of intrahepatic CXCL10 mRNA peaked (mean fold-induction [+/- SD], 1.3 +/- 0.54) at hour 10 or day 4. Peripheral CXCL10 levels were higher at treatment hour 10 (P = .032) and day 2 (P = .009) in patients with undetectable virus 2 weeks after treatment initiation. Treatment hour 10 (P = .023) and peak (P = .034) intrahepatic CXCL10 levels were also higher in these patients. CXCL10 did not distinguish treatment responders from non-responders. In conclusion, CXCL10 identified very rapid virological response in patients treated with a direct-acting antiviral. Clinical Trials Registration. NCT00892697.

引用

页码：1795 / 1799

页数：5

共 15 条

[1] Direct, Interferon-Independent Activation of the CXCL10 Promoter by NF-κB and Interferon Regulatory Factor 3 during Hepatitis C Virus Infection [J].

Brownell, Jessica ;

Bruckner, Jacob ;

Wagoner, Jessica ;

Thomas, Emmanuel ;

Loo, Yueh-Ming ;

Gale, Michael, Jr. ;

Liang, T. Jake ;

Polyak, Stephen J. .

JOURNAL OF VIROLOGY, 2014, 88 (03) :1582-1590

[2] Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes [J].

Brownell, Jessica ;

Wagoner, Jessica ;

Lovelace, Erica S. ;

Thirstrup, Derek ;

Mohar, Isaac ;

Smith, Wesley ;

Giugliano, Silvia ;

Li, Kui ;

Crispe, I. Nicholas ;

Rosen, Hugo R. ;

Polyak, Stephen J. .

JOURNAL OF HEPATOLOGY, 2013, 59 (04) :701-708

[3] Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C [J].

Butera, D ;

Marukian, S ;

Iwamaye, AE ;

Hembrador, E ;

Chambers, TJ ;

Di Bisceglie, AM ;

Charles, ED ;

Talal, AH ;

Jacobson, IM ;

Rice, CM ;

Dustin, LB .

BLOOD, 2005, 106 (04) :1175-1182

[4] Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates [J].

Li, Kui ;

Li, Nan L. ;

Wei, Dahai ;

Pfeffer, Susan R. ;

Fan, Meiyun ;

Pfeffer, Lawrence M. .

HEPATOLOGY, 2012, 55 (03) :666-675

[5] Interferon γ-Induced Protein10 Kinetics in Treatment-Naive Versus Treatment-Experienced Patients Receiving Interferon-Free Therapy for Hepatitis C Virus Infection: Implications for the Innate Immune Response [J].

Lin, Jennifer C. ;

Habersetzer, Francois ;

Rodriguez-Torres, Maribel ;

Afdhal, Nezam ;

Lawitz, Eric J. ;

Paulson, Matthew S. ;

Zhu, Yanni ;

Subramanian, Gangadharan Mani ;

McHutchison, John G. ;

Sulkowski, Mark ;

Wyles, David L. ;

Schooley, Robert T. .

JOURNAL OF INFECTIOUS DISEASES, 2014, 210 (12) :1881-1885

[6] Serum interferon-gamma-inducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C [J].

Matsuura, Kentaro ;

Watanabe, Tsunamasa ;

Iijima, Sayuki ;

Murakami, Shuko ;

Fujiwara, Kei ;

Orito, Etsuro ;

Iio, Etsuko ;

Endo, Mio ;

Kusakabe, Atsunori ;

Shinkai, Noboru ;

Miyaki, Tomokatsu ;

Nojiri, Shunsuke ;

Joh, Takashi ;

Tanaka, Yasuhito .

HEPATOLOGY RESEARCH, 2014, 44 (12) :1208-1216

[7] Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy [J].

Nishikawa, Hiroki ;

Enomoto, Hirayuki ;

Nasu, Akihiro ;

Aizawa, Nobuhiro ;

Saito, Masaki ;

Tamori, Akihiro ;

Kawada, Norifumi ;

Kimura, Toru ;

Osaki, Yukio ;

Nishiguchi, Shuhei .

HEPATOLOGY RESEARCH, 2014, 44 (14) :E397-E407

[8] Interferon (IFN)-γ-inducible protein-10:: Association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-α2a and ribavirin for chronic hepatitis C virus infection [J].

Romero, Ana I. ;

Lagging, Martin ;

Westin, Johan ;

Dhillon, Amar P. ;

Dustin, Lynn B. ;

Pawlotsky, Jean-Michel ;

Neumann, Avidan U. ;

Ferrari, Carlo ;

Missale, Gabriele ;

Haagmans, Bart L. ;

Schalm, Solko W. ;

Zeuzem, Stefan ;

Negro, Francesco ;

Verheij-Hart, Elke ;

Hellstrand, Kristoffer .

JOURNAL OF INFECTIOUS DISEASES, 2006, 194 (07) :895-903

[9] Telaprevir-Based Treatment Effects on Hepatitis C Virus in Liver and Blood [J].

Talal, Andrew H. ;

Dimova, Rositsa B. ;

Zhang, Eileen Z. ;

Jiang, Min ;

Penney, Marina S. ;

Sullivan, James C. ;

Botfield, Martyn C. ;

Chakilam, Ananthsrinivas ;

Sawant, Rishikesh ;

Cervini, Christine M. ;

Zeremski, Marija ;

Jacobson, Ira M. ;

Kwong, Ann D. .

HEPATOLOGY, 2014, 60 (06) :1826-1837

[10] The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection [J].

Zeremski, M. ;

Petrovic, L. M. ;

Talal, A. H. .

JOURNAL OF VIRAL HEPATITIS, 2007, 14 (10) :675-687

← 1 2 →